Vext Science, Inc.

As of June 30, 2026, Vext Science, Inc. carries a market capitalization of 35.17M, placing it among publicly traded companies globally. Its enterprise value stands at 60.76M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vext Science, Inc.'s next confirmed earnings release is scheduled for December 1, 2026.

As of June 30, 2026, Vext Science, Inc. has 247.71M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.74, and the price-to-book ratio stands at 0.74.

As of June 30, 2026, Vext Science, Inc. trades at an EV/EBITDA multiple of 8.67 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 60.76M versus a market cap of 35.17M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Vext Science, Inc. maintains a current ratio of 0.97, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 62.33, indicating elevated leverage, while an interest coverage ratio of 1.79 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Vext Science, Inc. posted a negative return on equity (ROE) of -22.99, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.51, reflecting losses generated across the asset base. The company generates approximately 253,491.88 in revenue per employee across its workforce of 175.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.88 indicates how many times Vext Science, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Vext Science, Inc. recorded 1.54M in income tax expense. The company reported a pretax loss of -11.06M and -12.60M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Vext Science, Inc.'s stock has gained approximately 1.84% over the past 52 weeks. The 50-day moving average sits at 0.16, while the 200-day moving average is 0.16.

Over the twelve months ended June 30, 2026, Vext Science, Inc. generated 44.36M in revenue and converted that into -12.60M in net income, yielding earnings per share of -0.05. EBITDA reached 7.01M, while operating income came in at -3.10M.

As of June 30, 2026, Vext Science, Inc. holds 3.97M in cash and equivalents against 29.56M in total debt, resulting in a net debt position of 22.11M. Total book value stands at 47.42M, with working capital of -801,774.80 providing operational flexibility.

Vext Science, Inc. produced 6.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.34M in capital expenditures, free cash flow totaled 3.01M - equivalent to 0.01 per share.

Over the twelve months ended June 30, 2026, Vext Science, Inc. posted a gross margin of 38.55, reflecting its pricing power and cost economics. The operating margin of -6.98 and net profit margin of -28.40 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 9.12, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vext Science, Inc. shareholders.

As of June 30, 2026, Vext Science, Inc. has an Altman Z-Score of 0.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.